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Abstract: 
Yellow fever virus is the causative agent of Yellow fever. The genome of the virus contains three structural and seven non-structural proteins. Of these seven non-
structural proteins, NS2B-NS3 protein complex has protease activity required for viral replication. Predicting the 3D structure of this complex and studying the 
interaction of residues at the recognized catalytic triad of the complex is an integral part to understand the virus replication mechanism. In the present study, the 
structure was determined for NS2B-NS3 complex by Homology modeling and modeled structure was validated for its stability. Mutation studies at the residues 
His94, Asp118 and Ser176 revealed that Asp118-His94 bond played an important role in the structural stability of NS2B-NS3 complex. This indicates site-directed 
mutagenesis, controlling YFV replication, as one mechanism to design vaccine strains. Docking studies of the bioactive compounds at the active site of NS2B-NS3 
complex also indicated 4-hydroxypanduratin A as potential lead compound for drug development. The theoretical models will further pave way to experimentally 
verify our mutation and docking studies, thus taking a lead in pharmacogenomics and drug development.    
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Background:  
Yellow fever is endemic in South America and in Sub-Saharan Africa. It was 
reported that 40,000 deaths occur in the endemic regions annually [1, 2]. The 
Yellow Fever Virus (YFV), causative agent of the Yellow fever disease is 
transmitted to vertebrates by mosquitoes during feeding. The RNA genome of 
YFV contains 10,862 nucleotides and encodes a large polyprotein precursor of 
3411 amino acid residues which consist of three structural proteins (C, prM and 
E) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, 
NS5)  [3].  Optimal activity of the NS3 serine protease is required for the 
maturation of the virus and the presence of the NS2B co-factor is a pre-
requisite for the optimal catalytic activity of NS3 [4]. Studies revealed that 
NS3, contains a serine proteinase catalytic triad within amino terminal regions 
of 181 amino acid residues and also it requires the 40 amino acid residues of 
NS2B for protease activity [5]. We focus on insilico modeling and mutation of 
YFV NS2B/NS3 serine protease complex. Three-dimensional models of the 
NS2B-NS3 complex would be extremely useful in design of pharmaceutical 
compounds. 
 
Methodology: 
Homology model building: 
The Modeller software package (mod9v7) was used to build the NS2B/NS3 
complex model [6]. The homology modelling of NS2B/NS3 complex of YFV 
was performed with WNV NS2B/NS3 in complex with Bz-nKRR-H (PDB ID: 
2FP7) as a template [7]. The model generated was then submitted to the 
SAVES server for evaluation of its quality using PROCHECK [8].  
 
Mutation and interaction studies: 
In NS2B-NS3 complex, residues His 94, Asp 118 and Ser 176 were mutated 
using Bioedit [9] and again modeled. To know the stability of complex, 
hydrogen bonds formed between the NS2B/NS3 complex was studied using 
CCP4 packages [10]. 
 
Docking studies: 
The docking of three competitive bioactive molecules, 4-hydroxypanduratin A, 
panduratin A and ester, onto the catalytic triad of the serine protease were 
performed using Autodock 4.0.1 (http://autodock.scripps.edu/). Polar hydrogen 
atoms were added to the model of YFV NS2B/NS3 complex and its non-polar 
hydrogen atoms were merged. Kollman charges were added to this molecule. 
For the ligands, non-polar hydrogen atoms were merged with Gasteiger charges 
assigned. All rotatable bonds of ligands were set to be rotatable. Docking was 
performed using genetic algorithm and lamarckian genetic algorithm methods. 
A population size of 150 and 10 millions energy evaluations were used for 50 
times searches, with a 60 x 60 x 60 dimension of grid box size and 0.375 Å 
grid spacing around the catalytic triad. Clustering histogram analyses were 
performed after the docking searches.  
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Results and Discussion: 
In this study, the crystal structure of WNV NS2B/NS3 in complex with Bz-
nKRR-H was chosen as template to generate the YFV NS2B/NS3 model. After 
modeling, mutations were done at the catalytic triad to study the stability of the 
modeled complex protein before and after mutation. Binding studies between 
inhibitors and YFV serine protease complex were studied by performing 
protein-ligand docking using Autodock 4.0.1. This program utilizes lamarckian 
genetic algorithm for configuration search and evaluates the energy using grid-
based molecular affinity potential.  
 
Homology model of NS2B/NS3complex: 
The overall sequence identity between YFV NS2B/NS3 complex and WNV 
NS2B/NS3 was 69%, and was successfully modeled (Figure 1). Validation 
through PROCHECK shows that model after minimization contains 80.4% of 
the amino acid residues in the most favoured region, 14.1% in allowed regions, 
3.8% in generously regions and 1.6% in disallowed region in Ramachandran 
plot. The RMSD value of the modeled NS2B-NS3 complex was found to be 
4.702 Å. The modeled structure was well within the described Ramachandran 
limits, and thus was considered to be the putative structure for NS2B-NS3 
complex for further studies. 
 
 
Figure 1: Three dimensional structure of YFV NS2B-NS3 complex modeled 
using Modeller9v7. The 2FP7 from WNV was used as template. NS2B is 
shown in red color and NS3 is shown in green color. 
 
Mutation at the catalytic triad: 
NS2B-NS3 complex has a catalytic triad comprising of His94, Asp118 and 
Ser176 which has the proteolytic activity [4], important for viral replication. 
Thus abolishing or dramatically reducing protease activity has the ability to 
control the viral replication and thus stop spreading yellow fever [4, 11, and 
12]. Taking this factor into account, an insilico mutation study was done and 
comparison was drawn between the wild and the mutant models. The sequence 
retrieved from swiss-prot was mutated at 3 residues (His94, Asp118 and Ser 
176) with 4 different combinations by using BioEdit software as tabularized 
below in Table 1 (see Supplementary material). After mutation the sequence 
was modeled and validated. 
 
Based on the three-dimensional structure of NS2B-NS3 complex, the hydrogen 
bonds in the active centre of NS2B-NS3 complex are discussed. As shown in 
Table 2 (see Supplementary material), there are five hydrogen bonds in the 
NS2B-NS3 complex. These hydrogen bonds are important because they are 
formed between the catalytic triad and also catalytic triad residues with other 
residues in the complex. Studies by Lau et al. (1999) [13], suggests that the 
breaking of Asp118-His94 hydrogen bond of the catalytic triad has drastic 
effect on the structure and dynamics of the protein. The instability induced in 
the structure may also be reasoned to substantiate the reduced catalytic activity 
of the protein. Hence H-bonds formed between the residues were taken as 
deciding factor for judging the level of activity of the catalytic triad in various 
mutated models.  
 
The effect of mutation was studied by considering the H-bonds formed within 
the catalytic triad. After mutation all bonds are formed, except one functionally 
important bond between His94 and Asp118 (Table 3a, See supplementary 
material). Asp118-His94 bond was prominent in the wild model but this bond 
was non-existent in all of the mutant models. The RMSD values of the mutated 
models are given in Table 3b (See supplementary material). From the values 
it is evident that the mutation of any of these residues disrupts the structure. 
Thus applying this study at molecular level may prove an important strategy for 
controlling the replication of Yellow Fever Virus.  
 
Docking:  
The discovery of potential ligands as drug candidates was an important aspect 
for controlling diseases like dengue, swine flu based on homology models [14]. 
Inhibitors namely 4-hydroxypanduratin A, Panduratin A and Ester were used as 
ligands for binding interaction studies with the active site of the DEN2 serine 
protease [15]. Since the active residues of catalytic triad are found to be same 
in serine proteases of all flavi virus, the same three inhibitors 4-
hydroxypanduratin A, Panduratin A and Ester are used in our docking studies. 
Docking analysis of the ligands 4-hydroxypanduratin A, Panduratin A and 
Ester with the NS2B-NS3 complex showed interesting pattern of interactions 
and binding mode to the active site. To have a better understanding of the 
interaction of ligands with the complex, binding energies as well as the 
hydrogen bond interactions, are tabulated in Table 4 (see Supplementary 
material). Among the three ligands screened, 4-hydroxypanduratin A was 
found to have best docking in terms of interaction and forming hydrogen bond 
with active site residue, Asp118 (Figure 2). The minimum binding energy 
indicated the strong affinity of 4-hydroxypanduratin A with the NS2B-NS3 
complex which had been stabilized by strong hydrogen bond interactions in the 
binding pocket.  
 
 
Figure 2: NS2B-NS3 complex docked with 4-hydroxypanduratin forming 
hydrogen bonds with Asp118 and Gly 195. 
 
Conclusion: 
Working at the catalytic triad of YFV is one important way of studying viral 
replication and can provide an insight into the way to prevent its replication. 
Current work can be considered as a preliminary approach in determining the 
3D structure of NS2B-NS3 complex. Docking studies of the 4-
hydroxypanduratin A compound also yielded satisfactory result and thus can be 
used as potential lead compounds for drug trials against YFV.  Thus structure 
validation, mutation and docking are approaches used to control YFV that 
needs to be potentially harnessed in lab and if successful, will prove a break in 
medical genetics. The SNP modification if carried out at molecular level will 
decrease viral activity and thus control viral replication leading to vaccine 
development. The X-ray crystallographic studies on our theoretically modeled 
NS2B-NS3 complex structure will lead to determination of 3D structure that 
may further help in the study of its mechanism. Mutation studies will help us 
determine the structure modification undergone due to instability of the 
structure.   
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Supplementary material: 
 
Table 1: Mutations at catalytic triad of NS2B-NS3 complex 
NS2B-NS3 complex  HIS 94  ASP 118  SER 176 
NS2B-NS3 Δ1  ALA  ALA  ALA 
NS2B-NS3 Δ2  ALA  ALA  CYS 
NS2B-NS3 Δ3  ALA  ASN  ALA 
NS2B-NS3 Δ4  ALA  ASN  CYS 
 
Table 2: Hydrogen bonds formed before mutation 
H-bond  Residue  1(B1) Atom Residue  2    (B2) Atom  B1-B2  distance  (Å) 
1  94 HIS  N  118 ASP  OD1  3.27 
2  94 HIS  N  118 ASP  OD2  3.28 
3  118 ASP  N  115 VAL  O  3.02 
4  118 ASP  N  114 SER  O  2.70 
5  179 SER  N  176 SER  O  3.19 
 
Table 3a: Hydrogen bonds formed after mutation  
H-bonds  Residue 1 (B1)  Atom  Residue 2  (B2)  Atom  B1-B2 distance  (Å) 
1  118 ASP  N  115 VAL  O  3.02 
2  118 ASP  N  114 SER  O  2.70 
3  179 SER  N  176 SER  O  3.19 
 
Table 3b: RMSD values of the mutated models 
Mutants RMSD(Å) 
NS2B-NS3 Δ1  15.952 
NS2B-NS3 Δ2  4.706 
NS2B-NS3 Δ3  4.798 
NS2B-NS3 Δ4  7.929 
 
Table 4: Docking of the ligands (4-hydroxypanduratin A, Panduratin A and Ester) with NS2B-NS3 complex 
Ligand Binding  Energy 
(kcal/mol) 
Number of 
Hydrogen bonds 
Inhibitory Constant 
(µM) 
Interacting with catalytic triad 
(His 94, Asp 118, Ser 176) 
4-hydroxypanduratin A  -5.44  2  103.73  Yes 
Panduratin A  -5.76  2  60.26  No 
Ester -4.27  4  740.49  No 
 
 
 
 
 